Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1994 Feb;111(2):609–615. doi: 10.1111/j.1476-5381.1994.tb14780.x

Endothelin receptors mediating functional responses in human small arteries and veins.

J Riezebos 1, I S Watts 1, P J Vallance 1
PMCID: PMC1909960  PMID: 8004404

Abstract

1. In the present study, responses of human omental small arteries and veins to endothelin-1 and endothelin-3 were characterized by use of the ETB receptor selective agonist, sarafotoxin S6c, the ETA receptor antagonist, BQ123, the ETB receptor antagonist, IRL1038, the NO-synthase inhibitor NG-monomethyl-L-arginine (L-NMMA, 300 microM) and indomethacin (10 microM). 2. Small arteries (internal diameter 413 +/- 22 microns) and parallel running veins (646 +/- 35 microns) were mounted in a myograph under a normalized tension equivalent to 90% of a transmural pressure of 100 mmHg and 19 mmHg in vivo, respectively. 3. In small arteries and veins, endothelin-1 caused a concentration-dependent increase in wall tension (Emax = 3.90 +/- 0.56 mN mm-1 and 1.90 m +/- 0.32 mN mm-1 respectively, P < 0.05) and was equipotent (arteries: pD2 = 8.91 +/- 0.11; veins: pD2 = 8.63 +/- 0.08, NS). In endothelium intact arteries, L-NMMA significantly enhanced the sensitivity to endothelin-1 (pD2 control: 8.92 +/- 0.16; pD2 L-NMMA: 9.37 +/- 0.11; P < 0.05). L-NMMA did not affect the sensitivity of veins to endothelin-1. Indomethacin was without effect in arteries and veins. In veins, endothelin-3 was about a hundred times less potent than endothelin-1 and showed a biphasic response curve. Small arteries did not contract to endothelin-3. Neither small arteries nor veins contracted to sarafotoxin S6c. Furthermore, no relaxation to endothelin-1 or sarafotoxin S6c was seen in any precontracted vessels.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
609

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990 Dec 20;348(6303):730–732. doi: 10.1038/348730a0. [DOI] [PubMed] [Google Scholar]
  3. Bax W. A., Bos E., Saxena P. R. Heterogeneity of endothelin/sarafotoxin receptors mediating contraction of the human isolated saphenous vein. Eur J Pharmacol. 1993 Aug 3;239(1-3):267–268. doi: 10.1016/0014-2999(93)91010-k. [DOI] [PubMed] [Google Scholar]
  4. Bigaud M., Pelton J. T. Discrimination between ETA- and ETB-receptor-mediated effects of endothelin-1 and [Ala1,3,11,15]endothelin-1 by BQ-123 in the anaesthetized rat. Br J Pharmacol. 1992 Dec;107(4):912–918. doi: 10.1111/j.1476-5381.1992.tb13385.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Borić M. P., Donoso V., Fournier A., St Pierre S., Huidobro-Toro J. P. Endothelin reduces microvascular blood flow by acting on arterioles and venules of the hamster cheek pouch. Eur J Pharmacol. 1990 Nov 6;190(1-2):123–133. doi: 10.1016/0014-2999(90)94119-i. [DOI] [PubMed] [Google Scholar]
  6. Brain S. D., Tippins J. R., Williams T. J. Endothelin induces potent microvascular constriction. Br J Pharmacol. 1988 Dec;95(4):1005–1007. doi: 10.1111/j.1476-5381.1988.tb11731.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cardell L. O., Uddman R., Edvinsson L. A novel ETA-receptor antagonist, FR 139317, inhibits endothelin-induced contractions of guinea-pig pulmonary arteries, but not trachea. Br J Pharmacol. 1993 Feb;108(2):448–452. doi: 10.1111/j.1476-5381.1993.tb12824.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cardell L. O., Uddman R., Edvinsson L. Evidence for multiple endothelin receptors in the guinea-pig pulmonary artery and trachea. Br J Pharmacol. 1992 Feb;105(2):376–380. doi: 10.1111/j.1476-5381.1992.tb14261.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Clarke J. G., Benjamin N., Larkin S. W., Webb D. J., Davies G. J., Maseri A. Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol. 1989 Dec;257(6 Pt 2):H2033–H2035. doi: 10.1152/ajpheart.1989.257.6.H2033. [DOI] [PubMed] [Google Scholar]
  10. Clozel M., Gray G. A., Breu V., Löffler B. M., Osterwalder R. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun. 1992 Jul 31;186(2):867–873. doi: 10.1016/0006-291x(92)90826-7. [DOI] [PubMed] [Google Scholar]
  11. Cocks T. M., Faulkner N. L., Sudhir K., Angus J. Reactivity of endothelin-1 on human and canine large veins compared with large arteries in vitro. Eur J Pharmacol. 1989 Nov 14;171(1):17–24. doi: 10.1016/0014-2999(89)90425-1. [DOI] [PubMed] [Google Scholar]
  12. Eglezos A., Cucchi P., Patacchini R., Quartara L., Maggi C. A., Mizrahi J. Differential effects of BQ-123 against endothelin-1 and endothelin-3 on the rat vas deferens: evidence for an atypical endothelin receptor. Br J Pharmacol. 1993 Jul;109(3):736–738. doi: 10.1111/j.1476-5381.1993.tb13635.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Fozard J. R., Part M. L. The role of nitric oxide in the regional vasodilator effects of endothelin-1 in the rat. Br J Pharmacol. 1992 Mar;105(3):744–750. doi: 10.1111/j.1476-5381.1992.tb09049.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Harrison V. J., Randriantsoa A., Schoeffter P. Heterogeneity of endothelin-sarafotoxin receptors mediating contraction of pig coronary artery. Br J Pharmacol. 1992 Mar;105(3):511–513. doi: 10.1111/j.1476-5381.1992.tb09009.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Haynes W. G., Webb D. J. Endothelium-dependent modulation of responses to endothelin-I in human veins. Clin Sci (Lond) 1993 Apr;84(4):427–433. doi: 10.1042/cs0840427. [DOI] [PubMed] [Google Scholar]
  16. Hiley C. R., Cowley D. J., Pelton J. T., Hargreaves A. C. BQ-123, cyclo(-D-Trp-D-Asp-Pro-D-Val-Leu), is a non-competitive antagonist of the actions of endothelin-1 in SK-N-MC human neuroblastoma cells. Biochem Biophys Res Commun. 1992 Apr 15;184(1):504–510. doi: 10.1016/0006-291x(92)91223-d. [DOI] [PubMed] [Google Scholar]
  17. Ihara M., Noguchi K., Saeki T., Fukuroda T., Tsuchida S., Kimura S., Fukami T., Ishikawa K., Nishikibe M., Yano M. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci. 1992;50(4):247–255. doi: 10.1016/0024-3205(92)90331-i. [DOI] [PubMed] [Google Scholar]
  18. Inoue A., Yanagisawa M., Kimura S., Kasuya Y., Miyauchi T., Goto K., Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A. 1989 Apr;86(8):2863–2867. doi: 10.1073/pnas.86.8.2863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Karaki H., Sudjarwo S. A., Hori M., Sakata K., Urade Y., Takai M., Okada T. ETB receptor antagonist, IRL 1038, selectively inhibits the endothelin-induced endothelium-dependent vascular relaxation. Eur J Pharmacol. 1993 Feb 16;231(3):371–374. doi: 10.1016/0014-2999(93)90112-u. [DOI] [PubMed] [Google Scholar]
  20. Kiowski W., Lüscher T. F., Linder L., Bühler F. R. Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation. 1991 Feb;83(2):469–475. doi: 10.1161/01.cir.83.2.469. [DOI] [PubMed] [Google Scholar]
  21. Kloog Y., Ambar I., Sokolovsky M., Kochva E., Wollberg Z., Bdolah A. Sarafotoxin, a novel vasoconstrictor peptide: phosphoinositide hydrolysis in rat heart and brain. Science. 1988 Oct 14;242(4876):268–270. doi: 10.1126/science.2845579. [DOI] [PubMed] [Google Scholar]
  22. Lamping K. G., Clothier J. L., Eastham C. L., Marcus M. L. Coronary microvascular response to endothelin is dependent on vessel diameter and route of administration. Am J Physiol. 1992 Sep;263(3 Pt 2):H703–H709. doi: 10.1152/ajpheart.1992.263.3.H703. [DOI] [PubMed] [Google Scholar]
  23. Lüscher T. F., Yang Z., Tschudi M., von Segesser L., Stulz P., Boulanger C., Siebenmann R., Turina M., Bühler F. R. Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins. Circ Res. 1990 Apr;66(4):1088–1094. doi: 10.1161/01.res.66.4.1088. [DOI] [PubMed] [Google Scholar]
  24. MacLean M. R., Templeton A. G., McGrath J. C. The influence of endothelin-1 on human foeto-placental blood vessels: a comparison with 5-hydroxytryptamine. Br J Pharmacol. 1992 Aug;106(4):937–941. doi: 10.1111/j.1476-5381.1992.tb14438.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. McNamara D. B., Light J. T., Minkes R. K., Saroyan R. M., Kvamme P., Rowe N., Webb W. R., Fox L., Kerstein M. D., Mills N. L. Comparative effects of endothelin (ET-1) and U46619 on human saphenous vein and gastroepiploic artery, sources of human autologous grafts. Mol Cell Biochem. 1992 Nov 4;117(1):81–85. doi: 10.1007/BF00230413. [DOI] [PubMed] [Google Scholar]
  26. Miller R. C., Pelton J. T., Huggins J. P. Endothelins--from receptors to medicine. Trends Pharmacol Sci. 1993 Feb;14(2):54–60. doi: 10.1016/0165-6147(93)90031-e. [DOI] [PubMed] [Google Scholar]
  27. Moreland S., McMullen D. M., Delaney C. L., Lee V. G., Hunt J. T. Venous smooth muscle contains vasoconstrictor ETB-like receptors. Biochem Biophys Res Commun. 1992 Apr 15;184(1):100–106. doi: 10.1016/0006-291x(92)91163-k. [DOI] [PubMed] [Google Scholar]
  28. Mulvany M. J., Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res. 1977 Jul;41(1):19–26. doi: 10.1161/01.res.41.1.19. [DOI] [PubMed] [Google Scholar]
  29. Rogerson M. E., Cairns H. S., Fairbanks L. D., Westwick J., Neild G. H. Endothelin-1 in the rabbit: interactions with cyclo-oxygenase and NO-synthase products. Br J Pharmacol. 1993 Mar;108(3):838–843. doi: 10.1111/j.1476-5381.1993.tb12887.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990 Dec 20;348(6303):732–735. doi: 10.1038/348732a0. [DOI] [PubMed] [Google Scholar]
  31. Salom J. B., Torregrosa G., Barberá M. D., Jover T., Alborch E. Endothelin receptors mediating contraction in goat cerebral arteries. Br J Pharmacol. 1993 Jul;109(3):826–830. doi: 10.1111/j.1476-5381.1993.tb13649.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Schiffrin E. L., Deng L. Y., Larochelle P. Blunted effects of endothelin upon small subcutaneous resistance arteries of mild essential hypertensive patients. J Hypertens. 1992 May;10(5):437–444. doi: 10.1097/00004872-199205000-00006. [DOI] [PubMed] [Google Scholar]
  33. Sudjarwo S. A., Hori M., Takai M., Urade Y., Okada T., Karaki H. A novel subtype of endothelin B receptor mediating contraction in swine pulmonary vein. Life Sci. 1993;53(5):431–437. doi: 10.1016/0024-3205(93)90647-l. [DOI] [PubMed] [Google Scholar]
  34. Sumner M. J., Cannon T. R., Mundin J. W., White D. G., Watts I. S. Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction. Br J Pharmacol. 1992 Nov;107(3):858–860. doi: 10.1111/j.1476-5381.1992.tb14537.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Taddei S., Vanhoutte P. M. Role of endothelium in endothelin-evoked contractions in the rat aorta. Hypertension. 1993 Jan;21(1):9–15. doi: 10.1161/01.hyp.21.1.9. [DOI] [PubMed] [Google Scholar]
  36. Urade Y., Fujitani Y., Oda K., Watakabe T., Umemura I., Takai M., Okada T., Sakata K., Karaki H. An endothelin B receptor-selective antagonist: IRL 1038, [Cys11-Cys15]-endothelin-1(11-21) FEBS Lett. 1992 Oct 12;311(1):12–16. doi: 10.1016/0014-5793(92)81355-p. [DOI] [PubMed] [Google Scholar]
  37. Vierhapper H., Wagner O., Nowotny P., Waldhäusl W. Effect of endothelin-1 in man. Circulation. 1990 Apr;81(4):1415–1418. doi: 10.1161/01.cir.81.4.1415. [DOI] [PubMed] [Google Scholar]
  38. Watt P. A., Baker A. R., Thurston H. Vasoconstrictor actions of endothelin-1 in human resistance vessels. J Hypertens Suppl. 1989 Dec;7(6):S134–S135. doi: 10.1097/00004872-198900076-00063. [DOI] [PubMed] [Google Scholar]
  39. Williams D. L., Jr, Jones K. L., Pettibone D. J., Lis E. V., Clineschmidt B. V. Sarafotoxin S6c: an agonist which distinguishes between endothelin receptor subtypes. Biochem Biophys Res Commun. 1991 Mar 15;175(2):556–561. doi: 10.1016/0006-291x(91)91601-8. [DOI] [PubMed] [Google Scholar]
  40. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988 Mar 31;332(6163):411–415. doi: 10.1038/332411a0. [DOI] [PubMed] [Google Scholar]
  41. Yasuda M., Kohno M., Tahara A., Itagane H., Toda I., Akioka K., Teragaki M., Oku H., Takeuchi K., Takeda T. Circulating immunoreactive endothelin in ischemic heart disease. Am Heart J. 1990 Apr;119(4):801–806. doi: 10.1016/s0002-8703(05)80315-1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES